Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
Status:
Completed
Trial end date:
2018-03-03
Target enrollment:
Participant gender:
Summary
The study is designed as a Phase III, multicenter trial of tandem autologous transplants plus
maintenance therapy versus the strategy of single autologous transplant plus consolidation
therapy with lenalidomide, bortezomib and dexamethasone (RVD) followed by maintenance therapy
or single autologous transplant plus maintenance therapy as part of upfront treatment of
multiple myeloma (MM). Lenalidomide will be used as maintenance therapy for three years in
all arms.
Phase:
Phase 3
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators:
Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI)